Obsidian Therapeutics Inc.
OBX
NASDAQ17.77
USD
-1.15
- -
CIK
0002130606
ISIN
US67448A1060
CUSIP
67448A106
Return %
Stock
S&P500
1Y
1.54
20.37
3Y
1.54
73.24
5Y
1.54
73.69
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1030 Massachusetts Avenue Cambridge MA United States of America 02138
- IPO Date
- Aug 4, 2026
- CIK
- 0002130606
- Website
- obsidiantx.com
- Similar Companies
- Business
- Obsidian Therapeutics, Inc. engages in the discovery, development, and commercialization of gene-regulatory therapies and related technologies for translational disease applications. Its platform focuses on engineered protein degradation and switchable protein expression modalities to control target protein function and therapeutic outcomes. The company concentrates on therapeutics addressing hematology, oncology, and other serious diseases through strategies that modulate intracellular targets, including transcription factors and other traditionally challenging proteins. Main products and services - Core platform technologies: Obsidian’s proprietary protein engineering platforms enabling inducible control of protein stability and expression, designed to enable tunable, reversible modulation of disease-relevant proteins; supporting modular design, rapid prototyping, and preclinical validation. - Therapeutic programs: Preclinical and development-stage product candidates leveraging the platform in areas such as oncology, immune-oncology, neurology, and metabolic diseases; each program aims to deliver precise temporal control of target biology to improve efficacy and safety profiles. - Research collaborations and service offerings: Collaborative research services and use of the company’s platform in partnerships with biopharma, academic institutions, and research consortia to advance target validation, lead optimization, and translational studies. - Discovery and screening services: High-throughput screening and assay development capabilities to identify modulators of intracellular targets using the company’s programmable protein systems. - Data generation and analytics: Bioinformatics and functional characterization services that support target engagement, pharmacodynamics, and mechanism-of-action studies for internal and partner programs. Latest major company changes - Strategic partnerships: Entered collaborations with biopharma entities to co-develop and co-fund specified therapeutic programs leveraging Obsidian’s targeted protein control technologies. - Funding rounds and capital actions: Completed financing events to support expanded preclinical programs, platform expansion, and translational studies, strengthening balance sheet and pipeline momentum. - Product development milestones: Progression of lead preclinical candidates into enhanced IND-enabling studies; expansion of the platform’s capacity to support additional target modalities and disease areas. - Corporate structure and branding: Refinements to corporate structure or leadership updates aligned with ongoing growth and pipeline maturation; organizational refinements to support scalable operations across research and development functions. - Operational expansion: Augmentation of manufacturing, preclinical testing capabilities, and external collaborations to accelerate program timelines and broaden geographic reach. Additional context - Industry and segments: Biotechnology focused on gene regulation, targeted protein degradation, and programmable protein expression; early- to mid-stage drug discovery and development company with translational research emphasis. - Target markets and customers: Partners in biopharma, academic and research institutions, and potential downstream payers and healthcare systems upon successful development and commercialization. - Geographic operations: Headquarters in the United States with research activities and collaboration footprints likely spanning multiple regions; potential clinical development in North America and Europe as programs advance. - Founding year and headquarters: Founded in the 2010s decade; headquarters location is in the United States. - Subsidiaries and parent relationships: Operates as an independent biotechnology company with potential subsidiary or affiliate arrangements tied to collaboration and manufacturing activities. Notes - The description reflects Obsidian Therapeutics’ focus on programmable protein control platforms and their application to therapeutic development, emphasizing the company’s core technologies, programs, and strategic movements.
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million